Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Fate Therapeutics (FATE) Misses Q3 EPS by 2c
November 5, 2019 5:11 PM ESTFate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.40), $0.02 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $2.43 million versus the consensus estimate of $1.79 million.
First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with RituximabReceived FDA Clearance of IND Application for FT596, an Off-the-Shelf, Multi-Antigen... More